Unknown

Dataset Information

0

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.

ABSTRACT: Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.

SUBMITTER: Martinez DR 

PROVIDER: S-EPMC8270748 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, w  ...[more]

Similar Datasets

Unknown Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.
| S-EPMC7852229 | biostudies-literature
Unknown The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice.
| S-EPMC8475296 | biostudies-literature
Unknown The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice.
| S-EPMC9095975 | biostudies-literature
Unknown Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice.
| S-EPMC8907250 | biostudies-literature
Unknown Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance.
| S-EPMC8661799 | biostudies-literature
Unknown Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.
| S-EPMC8669038 | biostudies-literature
Unknown Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.
| S-EPMC8238069 | biostudies-literature
Unknown BALB/c mice challenged with SARS-CoV-2 B.1.351 β variant cause pathophysiological and neurological changes within the lungs and brains.
| S-EPMC11524415 | biostudies-literature
Unknown SARS-CoV-2 Omicron variant: Characteristics and prevention.
| S-EPMC8693031 | biostudies-literature
Unknown Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
| S-EPMC7980225 | biostudies-literature